Tuberculosis has recently become a reemergent, serious by reacting with a putative idiotype-like KT receptor (KTR), which has been shown to be present even in taxonomically health problem for industrialized countries, as it continues to be for developing countries [1] . For the former, a special threat unrelated microorganisms such as Pneumocystis carinii [8, 9] . Interestingly, candidacidal antibodies, functionally equivalent is the occurrence of multidrug-resistant (MDR) Mycobacterium tuberculosis isolates [2] . While requiring the implementation to KTIdAb, have been purified from the vaginal fluid of rats experimentally infected with KTR-bearing C. albicans cells as of all known measures to combat the pathogen and the disease, this reemergence also calls for new approaches aimed at an well as from women, particularly those with recurrent vaginal candidiasis. Like KTIdAb, these human natural KT-like antiunderstanding of pathogenesis and protective immunity against the microbial challenger as well as devising novel immunotherreceptor antibodies, termed KTAb, have been shown to kill C. albicans cells in vitro, to be neutralized by MAb KT4 in their apeutic tools and strategies.
In antimycobacterial defense, cell-mediated immunity has candidacidal activity, and to confer immunoprotection by passive transfer in experimental models of candidiasis [10] . Realways been considered of utmost importance, while little, if any, role has generally been assigned to antibodies. To our cently, we have produced monoclonal KTIdAb (KTMAb) and recombinant KTIdAb in the single-chain format (KTScFv) knowledge, no anti-mycobacterial antibody endowed with bactericidal activity has ever been reported. from the spleen lymphocytes of animals immunized with MAb KT4 [11, 12] . KTMAb and KTScFv were, as KTIdAb, able to In previous studies, we have shown that serum or secretory immunoprotective yeast killer toxin -like anti-idiotypic antikill C. albicans cells in vitro, to bind to specific KTR on C. albicans cells, and, significantly, to exert a strong therapeutic bodies with candidacidal properties (KTIdAb) could be elicited in mice and rats by parenteral or mucosal idiotypic vaccination effect in an in vivo experimental model of vaginal candidiasis. The candidacidal activity of KTMAb and KTScFV was neutralwith a monoclonal antibody (MAb KT4) capable of neutralizing the activity of a wide-spectrum killer toxin (KT) from the ized by MAb KT4. A schematic representation of the reagents and their reciproyeast Pichia anomala against KT-sensitive Candida albicans cells [3 -7] . While KT is inactivated at physiologic temperacal activities is shown in figure 1 . Because of the apparent transphyletic nature of KTR and its potential expression in ture, KTIdAb were shown to mimic KT activity also at 37ЊC vivo, we are currently investigating the sensitivity of other medically important microorganisms to the activity of KT and KT-like antibodies. to 100 mL of enrichment fluid (Becton Dickinson). The vials were then incubated at 37ЊC with 5% CO 2 and read daily until the maximum growth index (999) was reached in the controls. Evaluation of mycobactericidal activity. To assess mycobactericidal activity, a colony-forming unit assay was done from the bacterial suspensions added to a selected KTAb (preparation 1), KTMAb (100 mg), KTScFv (10 mg), or the same reagents preincubated with MAb KT4, as well as PBS, irrelevant isotype-matched MAb, or irrelevant ScFv as controls, after 72 h of incubation. Ten microliters of each bacterial suspension was diluted 1:30 in PBS, and then 100 mL was dispensed on the surface of Middlebrook 7H11 agar plates (Difco). The plates were then incubated at 37ЊC with 5% CO 2 and examined for colony growth. Each experiment was done in triplicate for statistical purposes.
Immunofluorescence studies. The immunofluorescence assays were done by using biotinylated reagents. KT (0.250 mg/mL), purified KTAb (preparation 1; 0.175 mg/mL), KTMAb (1 mg/ mL), and KTScFv (0.5 mg/mL) were biotin-labeled by using a Figure 1 . Scheme of reagents and their reciprocal involved in previously described procedure [11, 12] . One milliliter of the broth idiotypic network of yeast killer phenomenon. KT, Pichia anomala culture of M. tuberculosis TMC 306 was centrifuged (2200 g for killer toxin; KTR, KT receptor; MAbKT4, KT-neutralizing mono-20 min), and the cell pellet was washed twice with sterile PBS. clonal antibody; KTIdAb, KT-like anti-idiotypic antibodies with microbicidal properties in the monoclonal (KTMAb) and single-chain
The pellet was then suspended in PBS; next, 20 mL of the bacterial (KTScFv) format; KTAb, KT-like anti-KTR antibodies with microbisuspension was put into each well of an immunofluorescence slide cidal properties. For each type of antibody molecule, 1 V region is and, after drying, fixed by gentle heating before treatment with shown.
biotinylated reagents according to a procedure previously described [11, 12] . As a negative control, the immunofluorescence assay was done by using, in the same procedure, PBS in place of with candidiasis as previously described [10] . In the present study, biotinylated reagents. Further experiments were carried out with KTAb preparations from 2 subjects (preparations 1 and 2) were used each labeled reagent mixed with MAb KT4. Competition experiseparately, and they corresponded to the same KTAb preparations ments were also performed between each biotinylated reagent and obtained from patients 1 and 8 as detailed elsewhere [10] .
each unlabeled reagent as previously described [12] . In addition, KT, KTAb, KTMAb, and KTScFv were adsorbed by mixing, each biotinylated reagent was also evaluated in the immunofluowith each reagent (90 mL), 10 mL of MAb KT4 (10 mg/mL) rescence procedure against the MDR isolate of M. tuberculosis properly purified from ascites fluid. Each mixture was kept overafter extensive adsorption with KT-susceptible C. albicans cells. night at 4ЊC. even though the inhibitory activity was more significant after 72 KT, KTAb, KTMAb, and KTScFv preparations were seen h of exposure. Significantly, KTAb preparations, including the to bind to the M. tuberculosis TMC 306 cell surface, as shown ones from 3 other patients previously characterized [10] , showed by immunofluorescence. Figure 3 is an example of mycobactea growth index decrease (calculated on day 13, when the unrial cell staining with a biotinylated KTMAb preparation. The treated control reached the maximum growth) that ranged from immunofluorescence reactivity of each biotinylated reagent was Ç60% to ú90% depending on the individual KTAb preparation neutralized by previous mixing with MAb KT4. All biotinyl-(data not shown). Differences in potency were likely due to ated reagents (KT, KTAb, KTMAb, and KTScFv) competed differing amounts of bactericidal KTAb in each preparation, with their own unlabeled form as well as with each other for which has been purified by affinity chromatography and has been binding to the surface of mycobacterial cells. When adsorbed shown to contain various anti-idiotypic antibodies with different with KT-susceptible C. albicans cells, each reagent lost its isotypes and proportion of KT-mimicking, true internal image ability to react with M. tuberculosis in the same experimental antibodies [10] . It must be noted that the most active anti-M. conditions. tuberculosis KTAb preparations used throughout this study (preparations 1 and 2) were also the most active against C. albicans [10], indirectly supporting a common receptor and mechanism of Discussion action. Nonetheless, more homogeneous and reproducible results Here we report that yeast killer toxin -like natural (human), were obtained when standardized reagents, such as KTMAb and or artificial (murine monoclonal and recombinant) antibodies, KTScFv, were used under the same experimental conditions. The previously characterized for being candidacidal [10 -12] , do reduction in the number of colony-forming units after treatment also exert a bactericidal activity in vitro against an MDR isolate of the mycobacterial suspensions with the above reagents in comparison with those enumerated before the treatment demonof M. tuberculosis. Data not shown here also demonstrated that strates the mycobactericidal activity of KT-like antibodies (data represent a new, potentially powerful tool, particularly in the fight against MDR M. tuberculosis infections. not shown).
The neutralization of the mycobactericidal effect of KT, KTAb, KTMAb, and KTScFv by preincubation with anti-KT
